NEW YORK--(BUSINESS WIRE)--May 30, 2019--
UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will
present at three investor conferences in June:
-
Jefferies 2019 Global Healthcare Conference
- Tuesday, June 4th
- 9:00AM Eastern Time
- New York, NY
- Goldman Sachs 40th Annual Global Healthcare Conference
- Wednesday, June 12th
- 1:20PM Pacific Time
- Rancho Palos Verdes, CA
- Raymond James Life Sciences and MedTech Conference
- Wednesday, June 19th
- 8:35AM Eastern Time
- New York, NY
A live audio webcast of each event will be available on the Investors
section of UroGen's website, www.urogen.com.
A replay of each webcast will be available on the website for
approximately two weeks.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical
company developing advanced non-surgical treatments to address unmet
needs in the field of urology, with a focus on uro-oncology. UroGen has
developed RTGel™ reverse-thermal hydrogel, a proprietary sustained
release, hydrogel-based platform technology that has the potential to
improve therapeutic profiles of existing drugs. UroGen’s sustained
release technology is designed to enable longer exposure of the urinary
tract tissue to medications, making local therapy a potentially more
effective treatment option. UroGen’s lead investigational candidates,
UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel)
for intravesical instillation, are designed to potentially ablate tumors
by non-surgical means and to treat several forms of non-muscle invasive
urothelial cancer, including low-grade upper tract urothelial cancer and
low-grade non-muscle invasive bladder cancer, respectively. UroGen is
headquartered in New York, NY with operations in Los Angeles, CA and
Israel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005221/en/
Source: UroGen Pharma Ltd.
UROGEN:
Kate Bechtold
Director, Corporate
Communications & Investor Relations
Kate.Bechtold@urogen.com
914-552-0456
